Literature DB >> 203533

Enhanced resistance against encephalomyocarditis virus infection in mice, induced by a nonviable Mycobacterium tuberculosis oil-droplet vaccine.

D L Lodmell, L C Ewalt.   

Abstract

Female C57B1/10 mice injected intravenously (i.v.) with nonviable Mycobacterium tuberculosis Jamaica cells associated with oil-droplet emulsions (WCV) were highly resistant to the i.v. injection of encephalomyocarditis virus (EMCV). Resistance to infection (87% survival) was detected from 1 week to at least 12 weeks after injection of WCV. Mice vaccinated i.v. also were resistant to intraperitoneal, subcutaneous, or intramuscular virus challenge, but were not resistant to intracranial challenge. Mice vaccinated intraperitoneally also were resistant to virus infection, whereas WCV administered intramuscularly or subcutaneously did not protect mice from virus injected by any route. Less than 50% of WCV mice that survived virus challenge possessed serum anti-EMCV-neutralizing antibody (less than 1:10), and none had detectable (less than 1:10) serum interferon. Interferon was not detected in sera of WCV mice from 4 to 144 h after i.v. injection of EMCV. Studies concerning the effects of WCV on EMCV infection suggest that mice may be protected by mechanisms that inhibit early viral replication and spread of virus to the central nervous system.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 203533      PMCID: PMC414071          DOI: 10.1128/iai.19.1.225-230.1978

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  25 in total

1.  Effect of silica on virus infections in mice and mouse tissue culture.

Authors:  H duBuy
Journal:  Infect Immun       Date:  1975-05       Impact factor: 3.441

2.  Immunomodulator-induced resistance against herpes simplex virus.

Authors:  P S Morahan; E R Kern; L A Glasgow
Journal:  Proc Soc Exp Biol Med       Date:  1977-04

3.  Antiviral activity of an extract of Brucella abortus: induction of interferon and immunopotentiation of host resistance.

Authors:  E R Kern; L A Glasgow; J C Overall
Journal:  Proc Soc Exp Biol Med       Date:  1976-07

4.  Activation of guinea pig macrophages by cell walls of Mycobacterium bovis, strain BCG.

Authors:  M T Kelly
Journal:  Cell Immunol       Date:  1976-10       Impact factor: 4.868

5.  Antiviral activity of Brucella abortus preparations; separation of active components.

Authors:  D S Feingold; G Keleti; J S Youngner
Journal:  Infect Immun       Date:  1976-03       Impact factor: 3.441

6.  Enhancement of immunity against murine syngeneic tumors by a fraction extracted from non-pathogenic mycobacteria.

Authors:  A Lamensans; L Chedid; E Lederer; J P Rosselet; R H Gustafson; H J Spencer; B Ludwig; F M Berger
Journal:  Proc Natl Acad Sci U S A       Date:  1975-09       Impact factor: 11.205

7.  Protection against herpes simplex virus infection in mice by Corynebacterium parvum.

Authors:  H Kirchner; H M Hirt; K Munk
Journal:  Infect Immun       Date:  1977-04       Impact factor: 3.441

8.  Nonspecific resistance against infection with Salmonella typhi and Salmonella typhimurium induced in mice by cord factor (trehalose-6,6'-dimycolate) and its analogues.

Authors:  E Yarkoni; A Bekierkunst
Journal:  Infect Immun       Date:  1976-11       Impact factor: 3.441

9.  Inhibition of vaccinia virus replication in skin of tuberculin-sensitized animals challenged with PPD.

Authors:  D L Lodmell; L C Ewalt; A L Notkins
Journal:  J Immunol       Date:  1976-11       Impact factor: 5.422

10.  An examination of the cytotoxic effects of silica on macrophages.

Authors:  A C Allison; J S Harington; M Birbeck
Journal:  J Exp Med       Date:  1966-08-01       Impact factor: 14.307

View more
  9 in total

1.  Role of interferon in mice in protection against influenza A virus by bacterial ribosomes together with membranal glycoproteins of Klebsiella pneumoniae as adjuvant.

Authors:  D Robert; J P Quillon; B Ivanoff; Y Beaudry; R Fontanges; G Normier; A M Pinel; L D D'hinterland
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

2.  Induction of enhanced resistance against encephalomyocarditis virus infection of mice by nonviable Mycobacterium tuberculosis: mechanisms of protection.

Authors:  D L Lodmell; L C Ewalt
Journal:  Infect Immun       Date:  1978-12       Impact factor: 3.441

3.  The gamma interferon (IFN-gamma) mimetic peptide IFN-gamma (95-133) prevents encephalomyocarditis virus infection both in tissue culture and in mice.

Authors:  Mustafa G Mujtaba; Chintak B Patel; Ravi A Patel; Lawrence O Flowers; Marjorie A Burkhart; Lilian W Waiboci; James Martin; Mohammad I Haider; Chulbul M Ahmed; Howard M Johnson
Journal:  Clin Vaccine Immunol       Date:  2006-08

4.  Mechanisms of enhanced resistance of Mycobacterium bovis BCG-treated mice to ectromelia virus infection.

Authors:  T Sakuma; T Suenaga; I Yoshida; M Azuma
Journal:  Infect Immun       Date:  1983-11       Impact factor: 3.441

Review 5.  BCG Vaccination: A potential tool against COVID-19 and COVID-19-like Black Swan incidents.

Authors:  Wenping Gong; Yingqing Mao; Yuexi Li; Yong Qi
Journal:  Int Immunopharmacol       Date:  2022-05-17       Impact factor: 5.714

Review 6.  BCG Vaccine-Induced Trained Immunity and COVID-19: Protective or Bystander?

Authors:  Khalid Muhammad; Helal F Hetta; Gopala Koneru; Gaber El-Saber Batiha; Abdelazeem M Algammal; Mahmoud Mabrok; Sara Magdy; Shrouk Sayed; Mai E AbuElmagd; Reham Elnemr; Mahmoud M Saad; Noura H Abd Ellah; Amal Hosni
Journal:  Infect Drug Resist       Date:  2021-03-23       Impact factor: 4.003

Review 7.  The double-sided effects of Mycobacterium Bovis bacillus Calmette-Guérin vaccine.

Authors:  Junli Li; Lingjun Zhan; Chuan Qin
Journal:  NPJ Vaccines       Date:  2021-01-25       Impact factor: 7.344

8.  Dynamic single-cell RNA sequencing reveals BCG vaccination curtails SARS-CoV-2 induced disease severity and lung inflammation.

Authors:  Alok K Singh; Rulin Wang; Kara A Lombardo; Monali Praharaj; C Korin Bullen; Peter Um; Stephanie Davis; Oliver Komm; Peter B Illei; Alvaro A Ordonez; Melissa Bahr; Joy Huang; Anuj Gupta; Kevin J Psoter; Sanjay K Jain; Trinity J Bivalacqua; Srinivasan Yegnasubramanian; William R Bishai
Journal:  bioRxiv       Date:  2022-03-15

Review 9.  The potential use of liposome-mediated antiviral therapy.

Authors:  W C Koff; I J Fidler
Journal:  Antiviral Res       Date:  1985-06       Impact factor: 5.970

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.